The company is a Korea-based company principally engaged in the development of cell therapy business. The Company is engaged in the development and manufacture of immuno-cancer cell therapy products and immunosuppressive cell therapy products. In addition, the Company is engaged in the provision of vitier platform as an antigen-specific killing t cell treatment, viranger platform as a gammadelta t cell gene therapy and vimedier platform-based technology as a myeloid suppressor cell therapy derived from umbilical cord blood. It is engaged in the research and development of new drugs such as acute myeloid leukemia (AML) and glioblastoma. The Company was established on February 1, 2013. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on August 25, 2021.
Headquarters
Banpo-Daero 222, Seocho-Gu
Seoul; Seoul;
Contact Details: Purchase the Vigencell Inc. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service